Abstract 4437: The relevance of aberrant FPGS splicing for ex vivo MTX resistance and clinical outcome in childhood acute lymphoblastic leukemia

MLA

Anna Wojtuszkiewicz, et al. “Abstract 4437: The Relevance of Aberrant FPGS Splicing for Ex Vivo MTX Resistance and Clinical Outcome in Childhood Acute Lymphoblastic Leukemia.” Cancer Research, vol. 75, Aug. 2015, p. 4437. EBSCOhost, https://doi.org/10.1158/1538-7445.am2015-4437.

APA

Anna Wojtuszkiewicz, Gertjan L. Kaspers, Godefridus J. Peters, Gerrit Jansen, Edwin Sonneveld, Jacqueline Cloos, Yehuda G. Assaraf, & Mirthe Hoekstra. (2015). Abstract 4437: The relevance of aberrant FPGS splicing for ex vivo MTX resistance and clinical outcome in childhood acute lymphoblastic leukemia. Cancer Research, 75, 4437. https://doi.org/10.1158/1538-7445.am2015-4437

Chicago

Anna Wojtuszkiewicz, Gertjan L. Kaspers, Godefridus J. Peters, Gerrit Jansen, Edwin Sonneveld, Jacqueline Cloos, Yehuda G. Assaraf, and Mirthe Hoekstra. 2015. “Abstract 4437: The Relevance of Aberrant FPGS Splicing for Ex Vivo MTX Resistance and Clinical Outcome in Childhood Acute Lymphoblastic Leukemia.” Cancer Research 75 (August): 4437. doi:10.1158/1538-7445.am2015-4437.